Šw‰ï”•\
Inatani M, Kohama I, Chu A
Two-year post-market surveillance of safety and clinical outcomes of iStent inject® W combined with phacoemulsification in Japanese eyes with open-angle glaucoma
7th Asia-Pacific Glaucoma Congress, Manila, Philippines SMX Convention Center, May 24-26
Two-year post-market surveillance of safety and clinical outcomes of iStent inject® W combined with phacoemulsification in Japanese eyes with open-angle glaucoma
7th Asia-Pacific Glaucoma Congress, Manila, Philippines SMX Convention Center, May 24-26
Shogo Arimura
A deep learning model can detect the eyes receiving glaucoma medications based on anterior segment images
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9
A deep learning model can detect the eyes receiving glaucoma medications based on anterior segment images
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9
Iwasaki K.
Surgical outcomes of Baerveldt glaucoma implant versus Ahmed glaucoma valve in neovascular glaucoma: A multicenter study
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9
Surgical outcomes of Baerveldt glaucoma implant versus Ahmed glaucoma valve in neovascular glaucoma: A multicenter study
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9
Takamura Y, Sugihara Y, Yamada Y, Morioka M, Gozawa M, Inatani M, J-CREST (Japan Clinical Retina Study Group)
Characterization of visually impaired pacients with diabetes mellitus in Japan
ARVO 2024 The Seattle Convention Center, Seattle, USA May 4-9
Characterization of visually impaired pacients with diabetes mellitus in Japan
ARVO 2024 The Seattle Convention Center, Seattle, USA May 4-9
Yamada Y, Ichihashi Y, Takamura Y, Hirano T, Shimura M, Yoneda K, Konno K, Inatani M
Flare levels after intravitreal injection of brolucizumab for diabetic macular edema
ARVO 2024 The Seattle Convention Center, Seattle, USA May 4-9
Flare levels after intravitreal injection of brolucizumab for diabetic macular edema
ARVO 2024 The Seattle Convention Center, Seattle, USA May 4-9
îà‘º@‰ÀO
“œ”A•a–Ô–ŒÇfŽ@ƒKƒCƒhƒ‰ƒCƒ“‚̉ü’ù‚ÉŒü‚¯‚Ä
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
“œ”A•a–Ô–ŒÇfŽ@ƒKƒCƒhƒ‰ƒCƒ“‚̉ü’ù‚ÉŒü‚¯‚Ä
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
îà‘º@‰ÀO
RVEGFŽ¡—ÃŽž‘ã‚̃Œ[ƒU[Œõ‹ÃŒÅ‚ƃXƒeƒƒCƒh‚ÌŠˆ—p–@
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
RVEGFŽ¡—ÃŽž‘ã‚̃Œ[ƒU[Œõ‹ÃŒÅ‚ƃXƒeƒƒCƒh‚ÌŠˆ—p–@
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
îà‘º@‰ÀO
“œ”A•a‰©”Á•‚Žî‚É‚¨‚¯‚éR VEGF Ž¡—ÂÌÅ“K‰»
‘æ40‰ñ“ú–{ŠázŠÂŠw‰ï
—ߘa6”N7ŒŽ19-20“ú@•Ÿ“‡Œ§ŒSŽRŽs
“œ”A•a‰©”Á•‚Žî‚É‚¨‚¯‚éR VEGF Ž¡—ÂÌÅ“K‰»
‘æ40‰ñ“ú–{ŠázŠÂŠw‰ï
—ߘa6”N7ŒŽ19-20“ú@•Ÿ“‡Œ§ŒSŽRŽs
ˆî’J@‘å
Stent infinite and iDose
New glaucoma surgery trend from overseas
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
Stent infinite and iDose
New glaucoma surgery trend from overseas
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
’Ò@—²G
—Γàᫎ‹_Œoǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é–Ô–Œ_Œoß×–E޲õ‚̃~ƒgƒRƒ“ƒhƒŠƒA—±Žq‰ðÍ
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
—Γàᫎ‹_Œoǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é–Ô–Œ_Œoß×–E޲õ‚̃~ƒgƒRƒ“ƒhƒŠƒA—±Žq‰ðÍ
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
Šâí•@Œ’‘¾˜Y
‘OŠá•”ŒŸ¸‚̃Aƒbƒvƒf[ƒg
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
‘OŠá•”ŒŸ¸‚̃Aƒbƒvƒf[ƒg
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@‹³ˆçƒZƒ~ƒi[
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
îà‘º@‰ÀO
“O’ê“¢˜_! “œ”A•a–Ô–ŒÇE‰©”Á•‚Žîf—ẪNƒŠƒjƒJƒ‹ƒNƒGƒXƒ`ƒ‡ƒ“(CQ)
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙ
“O’ê“¢˜_! “œ”A•a–Ô–ŒÇE‰©”Á•‚Žîf—ẪNƒŠƒjƒJƒ‹ƒNƒGƒXƒ`ƒ‡ƒ“(CQ)
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙ
îà‘º@‰ÀO
‚±‚ñ‚ÈŽžA‚Ç‚¤‘Å‚ÂH[–Ô–ŒƒŒ[ƒU[‚ðÄl‚µ‚悤[
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙ
‚±‚ñ‚ÈŽžA‚Ç‚¤‘Å‚ÂH[–Ô–ŒƒŒ[ƒU[‚ðÄl‚µ‚悤[
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙ
Šâí•@Œ’‘¾˜Y
—¬o˜HÄŒšp‚Ì“K‰ž
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙ
—¬o˜HÄŒšp‚Ì“K‰ž
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙ
‘哈GKA‚‘º‰ÀO
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éSGLT2‘jŠQ–ò‚̉e‹¿
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éSGLT2‘jŠQ–ò‚̉e‹¿
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
‚‘º@‰ÀO
–Ñ׌ŒŠÇᎂ©‚猩‚铜”A•a‰©”Á•‚Žîf—Ã
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
–Ñ׌ŒŠÇᎂ©‚猩‚铜”A•a‰©”Á•‚Žîf—Ã
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
‚‘º@‰ÀO
‘f–p‚È‹^–â‚ÉŒü‚«‡‚Á‚Ä•à‚ñ‚¾“œ”A•aŠá‡•¹Ç‚ÌŒ¤‹†
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
‘f–p‚È‹^–â‚ÉŒü‚«‡‚Á‚Ä•à‚ñ‚¾“œ”A•aŠá‡•¹Ç‚ÌŒ¤‹†
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
ˆî’J@‘å
Žs”̌㒲¸2”N¬Ñ‚Æ’·ŠúˆÀ‘S«‚𑬕ñ‚µ‚Ü‚·I
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒOƒ‰ƒEƒRƒXƒWƒƒƒpƒ“@ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
Žs”̌㒲¸2”N¬Ñ‚Æ’·ŠúˆÀ‘S«‚𑬕ñ‚µ‚Ü‚·I
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒOƒ‰ƒEƒRƒXƒWƒƒƒpƒ“@ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
ˆî’J@‘å
–ò•¨“®‘Ԃ𓥂܂¦‚½Ž¡—ÃAƒvƒ[ƒ`
—ΓàᎡ—ÂÌhWhatfs moreh
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@çŽõ»–ò@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
–ò•¨“®‘Ԃ𓥂܂¦‚½Ž¡—ÃAƒvƒ[ƒ`
—ΓàᎡ—ÂÌhWhatfs moreh
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@çŽõ»–ò@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
ˆî’J@‘å
ƒGƒrƒfƒ“ƒX‚©‚ç•R‰ð‚—ΓàᎡ—Ã`—Γàá“_Šá–òŠá“àˆÚs•Ò`
ƒGƒrƒfƒ“ƒX‚©‚ç•R‰ð‚—ΓàᎡ—Ã`‰ß‹ŽEŒ»ÝE–¢—ˆ`
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒ”ƒBƒAƒgƒŠƒX»–ò@ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰
ƒGƒrƒfƒ“ƒX‚©‚ç•R‰ð‚—ΓàᎡ—Ã`—Γàá“_Šá–òŠá“àˆÚs•Ò`
ƒGƒrƒfƒ“ƒX‚©‚ç•R‰ð‚—ΓàᎡ—Ã`‰ß‹ŽEŒ»ÝE–¢—ˆ`
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒ”ƒBƒAƒgƒŠƒX»–ò@ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰
ˆî’J@‘å
‘±”—Γàá‚ÌŽèp‚Í‚±‚¤‚·‚é‚ñ‚¾I
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒAƒ‹ƒRƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
‘±”—Γàá‚ÌŽèp‚Í‚±‚¤‚·‚é‚ñ‚¾I
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@ƒAƒ‹ƒRƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
îà‘º@‰ÀO
“«DME‚ɑ΂·‚é–Ñ׌ŒŠÇᎂðˆÓޝ‚µ‚½ƒoƒr[ƒXƒ‚‚É‚æ‚鎡—Ãí—ª
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@’†ŠO»–ò@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
“«DME‚ɑ΂·‚é–Ñ׌ŒŠÇᎂðˆÓޝ‚µ‚½ƒoƒr[ƒXƒ‚‚É‚æ‚鎡—Ãí—ª
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@’†ŠO»–ò@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
îà‘º@‰ÀO
“œ”A•a‚ł̎¸–¾ƒ[ƒ‚ð–ÚŽw‚µ‚Ä
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@‚í‚©‚à‚Æ»–ò@ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
“œ”A•a‚ł̎¸–¾ƒ[ƒ‚ð–ÚŽw‚µ‚Ä
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@‚í‚©‚à‚Æ»–ò@ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
îà‘º@‰ÀO
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDMEÇ—á‚É“Á’¥‚Í‚ ‚é‚©H
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}@ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[
—ߘa6”N6ŒŽ14-15“ú@@ÔâƒCƒ“ƒ^[ƒVƒeƒBƒRƒ“ƒtƒ@ƒŒƒ“ƒX
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDMEÇ—á‚É“Á’¥‚Í‚ ‚é‚©H
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}@ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[
—ߘa6”N6ŒŽ14-15“ú@@ÔâƒCƒ“ƒ^[ƒVƒeƒBƒRƒ“ƒtƒ@ƒŒƒ“ƒX
Œã‘ò@½
PDRŽèpA‚¨–ð‚¾‚¿ƒc[ƒ‹
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@“ú–{ƒAƒ‹ƒRƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N6ŒŽ14-15“ú@@ÔâƒCƒ“ƒ^[ƒVƒeƒBƒRƒ“ƒtƒ@ƒŒƒ“ƒX
PDRŽèpA‚¨–ð‚¾‚¿ƒc[ƒ‹
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@“ú–{ƒAƒ‹ƒRƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N6ŒŽ14-15“ú@@ÔâƒCƒ“ƒ^[ƒVƒeƒBƒRƒ“ƒtƒ@ƒŒƒ“ƒX
ˆî’J@‘å
—ΓàኳŽÒ‚Ì”’“àáŽèp
ƒNƒƒXƒI[ƒo[—ΓàኳŽÒ‚Ì”’“àáŽèp
‘æ63‰ñ“ú–{”’“àáŠw‰ï‘‰ï@çŽõ»–ò@ƒXƒC[ƒcƒZƒ~ƒi[
—ߘa6”N8ŒŽ23-24“ú@@“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@
—ΓàኳŽÒ‚Ì”’“àáŽèp
ƒNƒƒXƒI[ƒo[—ΓàኳŽÒ‚Ì”’“àáŽèp
‘æ63‰ñ“ú–{”’“àáŠw‰ï‘‰ï@çŽõ»–ò@ƒXƒC[ƒcƒZƒ~ƒi[
—ߘa6”N8ŒŽ23-24“ú@@“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@
ˆî’J@‘å
‚±‚±‚܂Ŗ£‚¹‚Ü‚·IHydrus®—Γàáƒ}ƒCƒNƒƒXƒeƒ“ƒg‚Ì“Á’¥‚ƃKƒCƒhƒ‰ƒCƒ“
V‚½‚ÈMIGSŽž‘ã‚Ì–‹ŠJ‚¯`‚±‚±‚܂Ŗ£‚¹‚Ü‚·IHydrus—Γàáƒ}ƒCƒNƒƒXƒeƒ“ƒg`
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@“ú–{ƒAƒ‹ƒRƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
‚±‚±‚܂Ŗ£‚¹‚Ü‚·IHydrus®—Γàáƒ}ƒCƒNƒƒXƒeƒ“ƒg‚Ì“Á’¥‚ƃKƒCƒhƒ‰ƒCƒ“
V‚½‚ÈMIGSŽž‘ã‚Ì–‹ŠJ‚¯`‚±‚±‚܂Ŗ£‚¹‚Ü‚·IHydrus—Γàáƒ}ƒCƒNƒƒXƒeƒ“ƒg`
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@“ú–{ƒAƒ‹ƒRƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
ˆî’J@‘å
‚܂Ƃ߂ĉðàI—ΓàáŽèpÅVƒ‰ƒCƒ“ƒiƒbƒv
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@ƒ[ƒgƒjƒbƒeƒ“@ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
‚܂Ƃ߂ĉðàI—ΓàáŽèpÅVƒ‰ƒCƒ“ƒiƒbƒv
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@ƒ[ƒgƒjƒbƒeƒ“@ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
Inatani M
Let me talk about the criteria for usage requirements for iStent inject W in Japan
Glaucos Lancheon seminar
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9
Let me talk about the criteria for usage requirements for iStent inject W in Japan
Glaucos Lancheon seminar
The 17th Joint Meeting of Japan-Korea-China Ophthalmologists, Congress Haneda Square, Nov 9
ˆî’J@‘å
V‚µ‚¢ƒvƒŒ[ƒg•t‚«—ΓàáƒCƒ“ƒvƒ‰ƒ“ƒgiƒA[ƒƒhƒNƒŠƒAƒpƒXj‚Ì Žg—pŒoŒ±
‘½—l‰»‚·‚é—ΓàáŽèp‚̃Aƒvƒ[ƒ`F4ƒ^ƒCƒv‚̃fƒoƒCƒX‘I‘ð‚ÆŽg‚¢‚±‚È‚µ`V‚µ‚¢MIGS‚Ì’ñˆÄ~VŒ^ƒCƒ“ƒvƒ‰ƒ“ƒg‚Ü‚Å`
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@JFCƒZ[ƒ‹ƒXƒvƒ‰ƒ“ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
V‚µ‚¢ƒvƒŒ[ƒg•t‚«—ΓàáƒCƒ“ƒvƒ‰ƒ“ƒgiƒA[ƒƒhƒNƒŠƒAƒpƒXj‚Ì Žg—pŒoŒ±
‘½—l‰»‚·‚é—ΓàáŽèp‚̃Aƒvƒ[ƒ`F4ƒ^ƒCƒv‚̃fƒoƒCƒX‘I‘ð‚ÆŽg‚¢‚±‚È‚µ`V‚µ‚¢MIGS‚Ì’ñˆÄ~VŒ^ƒCƒ“ƒvƒ‰ƒ“ƒg‚Ü‚Å`
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@JFCƒZ[ƒ‹ƒXƒvƒ‰ƒ“ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
ˆî’J@‘å
Žg—p—vŒ“™Šî€‚ÌŽå‚ȉü’ù“_‚ð‰ðà‚µ‚Ü‚·I
‘Šú—Γàá‚ւ̃Aƒvƒ[ƒ``”’“àáŽèp•¹—pŠá“àƒhƒŒ[ƒ“`Vol.4
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒOƒ‰ƒEƒRƒXƒWƒƒƒpƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
Žg—p—vŒ“™Šî€‚ÌŽå‚ȉü’ù“_‚ð‰ðà‚µ‚Ü‚·I
‘Šú—Γàá‚ւ̃Aƒvƒ[ƒ``”’“àáŽèp•¹—pŠá“àƒhƒŒ[ƒ“`Vol.4
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï@ƒOƒ‰ƒEƒRƒXƒWƒƒƒpƒ“@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
îà‘º@‰ÀO
V‚µ‚¢“œ”A•a‰©”Á•‚Žî‚ÌŽ¡—ÃIƒvƒVƒ‡ƒ“
‘æ63‰ñ“ú–{–Ô–ŒÉŽq‘ÌŠw‰ï‘‰ï@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}Дޮ‰ïŽÐƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N12ŒŽ7“ú@‘åã‘Û‰ï‹cê
V‚µ‚¢“œ”A•a‰©”Á•‚Žî‚ÌŽ¡—ÃIƒvƒVƒ‡ƒ“
‘æ63‰ñ“ú–{–Ô–ŒÉŽq‘ÌŠw‰ï‘‰ï@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}Дޮ‰ïŽÐƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa6”N12ŒŽ7“ú@‘åã‘Û‰ï‹cê
îà‘º@‰ÀO
“à‰È‚ÆŠá‰È‚̘AŒg‚ªŽ¸–¾‚©‚瓜”A•aгŽÒ‚ð‹~‚¤
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@‚í‚©‚à‚Æ»–òƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
“à‰È‚ÆŠá‰È‚̘AŒg‚ªŽ¸–¾‚©‚瓜”A•aгŽÒ‚ð‹~‚¤
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@‚í‚©‚à‚Æ»–òƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
ŽR“c—Y‹MAŽs‹´—SŽuA‚‘º‰ÀOA•½–ì—²—YAŽu‘º‰ë•FA•Ä“cŒ\—CA¡–ìŒbˆê˜YAˆî’J‘å
“œ”A•a«‰©”Á•‚Žî‚ɑ΂·‚éƒuƒƒ‹ƒVƒYƒ}ƒuÉŽq‘Ì“à’ŽËŒã‚Ì‘O–[“àƒtƒŒƒA‚̕ω»
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
“œ”A•a«‰©”Á•‚Žî‚ɑ΂·‚éƒuƒƒ‹ƒVƒYƒ}ƒuÉŽq‘Ì“à’ŽËŒã‚Ì‘O–[“àƒtƒŒƒA‚̕ω»
‘æ128‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï@
—ߘa6”N4ŒŽ18-21“ú@@“Œ‹ž‘ÛƒtƒH[ƒ‰ƒ€
™Œ´—F‰ÀAîà‘º‰ÀOAŽR“c—Y‹MA·‰ª³˜aAŒã‘ò½A‰Á“¡‹v”üŽqA•½–ì‰À’jA‘º”öŽjŽqA´…”ü•äA“팴呾˜YA‰ª–{–FŽjA’|’†—DŠóA‰ª•”’¼ŽqAdé’BÆAŽ›èŠ°lA‰i—¢‘å—SA“Ÿk‰FA‹g“c–ζA¬–¸r‘¾˜YAˆÀ“c ‰À“ÞŽqA΋½‰ª AàV“cCA“Œ“‡Žj–¾Aˆî’J‘å
Ž‹ŠoáŠQŽÒŽè’ ‚ðŽæ“¾‚µ‚½“œ”A•aгŽÒ‚É‚¨‚¯‚éŽÀ‘Ô’²¸
‘æ25‰ñ“ú–{ƒ[ƒrƒWƒ‡ƒ“Šw‰ï
—ߘa6”N5ŒŽ24-26“ú@@‚³‚¢‚½‚ÜŽs
Ž‹ŠoáŠQŽÒŽè’ ‚ðŽæ“¾‚µ‚½“œ”A•aгŽÒ‚É‚¨‚¯‚éŽÀ‘Ô’²¸
‘æ25‰ñ“ú–{ƒ[ƒrƒWƒ‡ƒ“Šw‰ï
—ߘa6”N5ŒŽ24-26“ú@@‚³‚¢‚½‚ÜŽs
ŽR“c—Y‹MA‚‘º ‰ÀOA™Œ´ —F‰ÀAˆî’J ‘åAJ-CREST group
“œ”A•aгŽÒ‚ªŽ‹Šogá‚Æ‚È‚Á‚½”wŒi‚ÉŠÖ‚·‚é‘S‘’²¸
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@
—ߘa6”N6ŒŽ14-15“ú@ÔâƒCƒ“ƒ^[ƒVƒeƒBƒRƒ“ƒ“ƒtƒ@ƒŒƒ“ƒX
“œ”A•aгŽÒ‚ªŽ‹Šogá‚Æ‚È‚Á‚½”wŒi‚ÉŠÖ‚·‚é‘S‘’²¸
‘æ30‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï@
—ߘa6”N6ŒŽ14-15“ú@ÔâƒCƒ“ƒ^[ƒVƒeƒBƒRƒ“ƒ“ƒtƒ@ƒŒƒ“ƒX
’Ò@—²G
CD157 ƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚Ö‚ÌL-ƒJƒ‹ƒmƒVƒ“‚ÌŒoŒû“Š—^‚Í‹}«ƒXƒgƒŒƒX‚É‚æ‚è㸂·‚éƒRƒ‹ƒ`ƒRƒXƒeƒƒ“‚ðŒ¸Žã‚µA•ª—ls“®‚ð—}§‚·‚é
NEURO2024
—ߘa6”N7ŒŽ24-27“ú@•Ÿ‰ªƒRƒ“ƒxƒ“ƒVƒ‡ƒ“ƒZƒ“ƒ^[
CD157 ƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚Ö‚ÌL-ƒJƒ‹ƒmƒVƒ“‚ÌŒoŒû“Š—^‚Í‹}«ƒXƒgƒŒƒX‚É‚æ‚è㸂·‚éƒRƒ‹ƒ`ƒRƒXƒeƒƒ“‚ðŒ¸Žã‚µA•ª—ls“®‚ð—}§‚·‚é
NEURO2024
—ߘa6”N7ŒŽ24-27“ú@•Ÿ‰ªƒRƒ“ƒxƒ“ƒVƒ‡ƒ“ƒZƒ“ƒ^[
Šâ핌’‘¾˜YAˆî’J‘å
Surgical outcomes of Baerveldt versus Ahmed in neovascular glaucoma: A multicenter study
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
Surgical outcomes of Baerveldt versus Ahmed in neovascular glaucoma: A multicenter study
‘æ35‰ñ“ú–{—ΓàáŠw‰ï@
—ߘa6”N9ŒŽ19-22“ú@@ƒAƒNƒŠƒG‚Ђ߂¶
—L‘º®ŒåAˆî’J‘å
[‘wŠwKƒ‚ƒfƒ‹‚É‚æ‚é—Γàá“_ŠáŽ¡—Â̗L–³‚Ì”»–¾
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
[‘wŠwKƒ‚ƒfƒ‹‚É‚æ‚é—Γàá“_ŠáŽ¡—Â̗L–³‚Ì”»–¾
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
’Ò—²GA‰|–{’ˆêAˆî’J‘å
‚¤‚ÁŒŒ“û“ª‚𔺂¤Ž‹_ŒoÒ‘‰Š‚Ì1—á
‘æ62‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï
—ߘa6”N11ŒŽ29-30“ú@‹à‘òŽs
‚¤‚ÁŒŒ“û“ª‚𔺂¤Ž‹_ŒoÒ‘‰Š‚Ì1—á
‘æ62‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï
—ߘa6”N11ŒŽ29-30“ú@‹à‘òŽs
’O‰H@O‚
”]“®–¬áŽ”j—ô‚É‚æ‚é‚‚à–Œ‰ºoŒŒŒã‚É—¼ŠáŒõŠo‘rޏ‚ƂȂÁ‚½1—á
‘æ62‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï
—ߘa6”N11ŒŽ29-30“ú@‹à‘òŽs
”]“®–¬áŽ”j—ô‚É‚æ‚é‚‚à–Œ‰ºoŒŒŒã‚É—¼ŠáŒõŠo‘rޏ‚ƂȂÁ‚½1—á
‘æ62‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï
—ߘa6”N11ŒŽ29-30“ú@‹à‘òŽs
·‰ª³˜aAŽR“c—Y‹MA‚‘º‰ÀOAˆî’J‘åAJ-CREST group
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éÉŽq‘ÌŽèp‚Ì—LŒø«‚ÉŠÖ‚·‚鑽Ž{Ý•]‰¿
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éÉŽq‘ÌŽèp‚Ì—LŒø«‚ÉŠÖ‚·‚鑽Ž{Ý•]‰¿
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
îà‘º‰ÀOAŽR“c—Y‹MA·‰ª³˜aAˆî’J‘å
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éƒtƒ@ƒŠƒVƒ}ƒu“Š—^Œã‚ÌŽc‘¶•‚Žî‚É‚¨‚¯‚é–Ñ׌ŒŠÇᎂ̉ðÍ
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
“œ”A•a‰©”Á•‚Žî‚ɑ΂·‚éƒtƒ@ƒŠƒVƒ}ƒu“Š—^Œã‚ÌŽc‘¶•‚Žî‚É‚¨‚¯‚é–Ñ׌ŒŠÇᎂ̉ðÍ
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
¼ˆäç—mA™Œ´—F‰ÀAîà‘º‰ÀOA“c’†”gAŽR“c—Y‹MA–Ú•“”A”ª“c‘ñ–çA•y“c—œ¶A“ì’J—R”üŽqAˆî’J‘å
“œ”A•aгŽÒ‚ɑ΂·‚éƒ[ƒrƒWƒ‡ƒ“ƒPƒA‚ÌÅ“K‰»‚Ö‚ÌŽŽ‚Ý
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
“œ”A•aгŽÒ‚ɑ΂·‚éƒ[ƒrƒWƒ‡ƒ“ƒPƒA‚ÌÅ“K‰»‚Ö‚ÌŽŽ‚Ý
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
Œã‘ò½A܈ä—C‰îA‚‘º‰ÀOAˆî’J‘å
A case of globe rupture crossing calcified senile scleral plaque
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
A case of globe rupture crossing calcified senile scleral plaque
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
Šâ핌’‘¾˜YAˆî’J‘å
IOP lowering effect of IOL refixation in eyes with high IOP by IOL subluxation
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
IOP lowering effect of IOL refixation in eyes with high IOP by IOL subluxation
‘æ78‰ñ“ú–{—Õ°Šá‰ÈŠw‰ï
—ߘa6”N11ŒŽ14-17“ú@@‘—§‹ž“s‘Û‰ïŠÙEƒUEƒvƒŠƒ“ƒX‹ž“s•óƒ–’r
—L‘º®ŒåAŠâ핌’‘¾˜YA—é–Ø–œ—ŒbAˆî’J‘å
Grad-CAM‚ð—p‚¢‚½—Γàá”»•Ê‹@ŠBŠwKƒ‚ƒfƒ‹‚É‚¨‚¯‚é”»’fª‹’‚̉Ž‹‰»
‘æ5‰ñ“ú–{Šá‰ÈAIŠw‰ï‘‰ï
—ߘa6”N12ŒŽ1“ú@‹ãB‘åŠwˆãŠw•” •S”Nu“°
Grad-CAM‚ð—p‚¢‚½—Γàá”»•Ê‹@ŠBŠwKƒ‚ƒfƒ‹‚É‚¨‚¯‚é”»’fª‹’‚̉Ž‹‰»
‘æ5‰ñ“ú–{Šá‰ÈAIŠw‰ï‘‰ï
—ߘa6”N12ŒŽ1“ú@‹ãB‘åŠwˆãŠw•” •S”Nu“°
™Œ´—F‰ÀAîà‘º‰ÀOAŒã‘ò½AŽR“c—Y‹MA·‰ª³˜aAˆî’J‘å
•Ÿˆä‘åŠw‚ƉH“ñd‚Ë‚Á‚Ƃɂæ‚é•“I‚ȃ[ƒrƒWƒ‡ƒ“Žx‰‡
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
•Ÿˆä‘åŠw‚ƉH“ñd‚Ë‚Á‚Ƃɂæ‚é•“I‚ȃ[ƒrƒWƒ‡ƒ“Žx‰‡
‘æ31‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï
—ߘa7”N1ŒŽ25-26“ú@@‰«“êŽs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2024‹à‘òŠá‰ÈW’k‰ïƒXƒyƒVƒƒƒ‹I
‘æ352‰ñ‹à‘òŠá‰ÈW’k‰ïh™ŽR˜a‹v‹³Žö‚²‘Þ”C‹L”Oh@
—ߘa6”N4ŒŽ7“ú@Î쌧‹à‘òŽs
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2024‹à‘òŠá‰ÈW’k‰ïƒXƒyƒVƒƒƒ‹I
‘æ352‰ñ‹à‘òŠá‰ÈW’k‰ïh™ŽR˜a‹v‹³Žö‚²‘Þ”C‹L”Oh@
—ߘa6”N4ŒŽ7“ú@Î쌧‹à‘òŽs
ˆî’J@‘å
Å‘¬‚ł킩‚é—Γàá2024
–L’†ŽsˆãŽt‰ïŠá‰Èˆã‰ïŠwpŒ¤‹†‰ï
—ߘa6”N5ŒŽ11“ú@‘åã•{–L’†Žs
Å‘¬‚ł킩‚é—Γàá2024
–L’†ŽsˆãŽt‰ïŠá‰Èˆã‰ïŠwpŒ¤‹†‰ï
—ߘa6”N5ŒŽ11“ú@‘åã•{–L’†Žs
‚‘º@‰ÀO
“«DME‚ɑ΂µ‚ăoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚·Ž¡—Ãí—ª
’†ŠOeƒZƒ~ƒi[on Ophthalmology
—ߘa6”N5ŒŽ16“ú@WEB”zM
“«DME‚ɑ΂µ‚ăoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚·Ž¡—Ãí—ª
’†ŠOeƒZƒ~ƒi[on Ophthalmology
—ߘa6”N5ŒŽ16“ú@WEB”zM
ŽR“c@—Y‹M
–Ñ׌ŒŠÇᎂ©‚猩‚éRVEGF–òŽ¡—Ã’ïR«‚Ì“œ”A•a‰©”Á•‚Žî
GIFU Training of Ophthalmology
—ߘa6”N5ŒŽ23“ú@WEB”zM
–Ñ׌ŒŠÇᎂ©‚猩‚éRVEGF–òŽ¡—Ã’ïR«‚Ì“œ”A•a‰©”Á•‚Žî
GIFU Training of Ophthalmology
—ߘa6”N5ŒŽ23“ú@WEB”zM
‚‘º@‰ÀO
“«DME‚ɑ΂·‚é–Ñ׌ŒŠÇᎂðˆÓޝ‚µ‚½ƒoƒr[ƒXƒ‚‚É‚æ‚鎡—Ãí—ª
Faricimab Expert Seminar in Himeji
—ߘa6”N5ŒŽ31“ú@•ºŒÉŒ§•P˜HŽs
“«DME‚ɑ΂·‚é–Ñ׌ŒŠÇᎂðˆÓޝ‚µ‚½ƒoƒr[ƒXƒ‚‚É‚æ‚鎡—Ãí—ª
Faricimab Expert Seminar in Himeji
—ߘa6”N5ŒŽ31“ú@•ºŒÉŒ§•P˜HŽs
‚‘º@‰ÀO
ƒxƒIƒrƒ…‚ª—LŒø‚ÈDMEÇ—á‚É“Á’¥‚Í‚ ‚é‚©H
DME EXPERT MEETING IN TOKYO
—ߘa6”N6ŒŽ1“ú@@ƒOƒ‰ƒ“ƒhƒjƒbƒR[“Œ‹ž‘äê
ƒxƒIƒrƒ…‚ª—LŒø‚ÈDMEÇ—á‚É“Á’¥‚Í‚ ‚é‚©H
DME EXPERT MEETING IN TOKYO
—ߘa6”N6ŒŽ1“ú@@ƒOƒ‰ƒ“ƒhƒjƒbƒR[“Œ‹ž‘äê
‚‘º@‰ÀO
ƒGƒrƒfƒ“ƒX‚ÉŠî‚“«DMEŽ¡—Ãí—ª‚Ì\’z‚ð–ÚŽw‚µ‚Ä
‘æ17‰ñState-of-the-Art webŠá‰ÈŒ¤‹†‰ï
—ߘa6”N6ŒŽ3“ú@WEB”zM
ƒGƒrƒfƒ“ƒX‚ÉŠî‚“«DMEŽ¡—Ãí—ª‚Ì\’z‚ð–ÚŽw‚µ‚Ä
‘æ17‰ñState-of-the-Art webŠá‰ÈŒ¤‹†‰ï
—ߘa6”N6ŒŽ3“ú@WEB”zM
‚‘º@‰ÀO
ƒGƒrƒfƒ“ƒX‚ÉŠî‚“«DME‚ÌŽ¡—Ãí—ª\’z‚ð–ÚŽw‚µ‚Ä
DMEfŽ@ƒGƒLƒXƒp[ƒgƒtƒH[ƒ‰ƒ€
—ߘa6”N6ŒŽ9“ú@–kŠC“¹ŽD–yŽs
ƒGƒrƒfƒ“ƒX‚ÉŠî‚“«DME‚ÌŽ¡—Ãí—ª\’z‚ð–ÚŽw‚µ‚Ä
DMEfŽ@ƒGƒLƒXƒp[ƒgƒtƒH[ƒ‰ƒ€
—ߘa6”N6ŒŽ9“ú@–kŠC“¹ŽD–yŽs
‚‘º@‰ÀO
DMEŽ¡—Âɂ¨‚¢‚ăxƒIƒrƒ…‚ª—LŒø‚ÈÇ—á‚É“Á’¥‚Í‚ ‚é‚©H
Novartis DME Web Seminar
—ߘa6”N6ŒŽ19“ú@WEB”zM
DMEŽ¡—Âɂ¨‚¢‚ăxƒIƒrƒ…‚ª—LŒø‚ÈÇ—á‚É“Á’¥‚Í‚ ‚é‚©H
Novartis DME Web Seminar
—ߘa6”N6ŒŽ19“ú@WEB”zM
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2024
‘æ15‰ñ“Œ–M‘åŠw²‘q•a‰@Šá‰ÈƒtƒH[ƒ‰ƒ€
—ߘa6”N6ŒŽ22“ú@ç—tŽs
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2024
‘æ15‰ñ“Œ–M‘åŠw²‘q•a‰@Šá‰ÈƒtƒH[ƒ‰ƒ€
—ߘa6”N6ŒŽ22“ú@ç—tŽs
‚‘º@‰ÀO
“«DME‚ÌŽ•ž‚ð–ÚŽw‚¹‚éƒoƒr[ƒXƒ‚‚Ì“Á«
CHUGAI Ophthalmology Symposium 2024 in Osaka
—ߘa6”N6ŒŽ22“ú@‘åãŽs
“«DME‚ÌŽ•ž‚ð–ÚŽw‚¹‚éƒoƒr[ƒXƒ‚‚Ì“Á«
CHUGAI Ophthalmology Symposium 2024 in Osaka
—ߘa6”N6ŒŽ22“ú@‘åãŽs
‚‘º@‰ÀO
“«DME‚ɑ΂µ‚ăoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚·Ž¡—Ãí—ª
‘æ4‰ñL“‡–Ô–Œ‰©”Á޾гƒZƒ~ƒi[
—ߘa6”N6ŒŽ27“ú@Web”zM
“«DME‚ɑ΂µ‚ăoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚·Ž¡—Ãí—ª
‘æ4‰ñL“‡–Ô–Œ‰©”Á޾гƒZƒ~ƒi[
—ߘa6”N6ŒŽ27“ú@Web”zM
‚‘º@‰ÀO
“«DME‚ɑ΂µ‚ătƒ@ƒŠƒVƒ}ƒu‚Ì“Á«‚ð¶‚©‚¹‚é‚©H
“Þ—ÇŒ§Šá‰È–œ—tƒtƒH[ƒ‰ƒ€
—ߘa6”N6ŒŽ29“ú@“Þ—ÇŒ§Š€Œ´Žs
“«DME‚ɑ΂µ‚ătƒ@ƒŠƒVƒ}ƒu‚Ì“Á«‚ð¶‚©‚¹‚é‚©H
“Þ—ÇŒ§Šá‰È–œ—tƒtƒH[ƒ‰ƒ€
—ߘa6”N6ŒŽ29“ú@“Þ—ÇŒ§Š€Œ´Žs
ˆî’J@‘å
y‚ä‚Á‚‚è‰ðàz—Γàá“_Šá–ò2024
Pearls of Glaucoma 2024
—ߘa6”N7ŒŽ13“ú@–¼ŒÃ‰®Žs
y‚ä‚Á‚‚è‰ðàz—Γàá“_Šá–ò2024
Pearls of Glaucoma 2024
—ߘa6”N7ŒŽ13“ú@–¼ŒÃ‰®Žs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2024
’¹ŽæŒ§Šá‰ÈƒtƒH[ƒ‰ƒ€
—ߘa6”N7ŒŽ20“ú@@’¹ŽæŒ§•ÄŽqŽs
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2024
’¹ŽæŒ§Šá‰ÈƒtƒH[ƒ‰ƒ€
—ߘa6”N7ŒŽ20“ú@@’¹ŽæŒ§•ÄŽqŽs
ˆî’J@‘å
Å‘¬‚ł킩‚é—ΓàᎡ—Ã2024
Otsuka Ophthalmology Seminar in •Ÿˆä
—ߘa6”N7ŒŽ26“ú@@•Ÿˆä¤H‰ï‹cŠ
Å‘¬‚ł킩‚é—ΓàᎡ—Ã2024
Otsuka Ophthalmology Seminar in •Ÿˆä
—ߘa6”N7ŒŽ26“ú@@•Ÿˆä¤H‰ï‹cŠ
‚‘º@‰ÀO
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDMEÇ—á‚Ì“Á’¥‚ðl‚¦‚悤
ì‘åŠw-ˆ¤•Q‘åŠw‡“¯ƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa6”N7ŒŽ27“ú@@‚¼Žs
ƒxƒIƒrƒ…‚ª’˜Œø‚·‚éDMEÇ—á‚Ì“Á’¥‚ðl‚¦‚悤
ì‘åŠw-ˆ¤•Q‘åŠw‡“¯ƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa6”N7ŒŽ27“ú@@‚¼Žs
ˆî’J@‘å
y‚ä‚Á‚‚è‰ðàz—ΓàáŽèpƒAƒbƒvƒf[ƒg2024
‘æ45‰ñ“ŒŠC—Γàá‚̉ï
—ߘa6”N7ŒŽ28“ú@–¼ŒÃ‰®Žs
y‚ä‚Á‚‚è‰ðàz—ΓàáŽèpƒAƒbƒvƒf[ƒg2024
‘æ45‰ñ“ŒŠC—Γàá‚̉ï
—ߘa6”N7ŒŽ28“ú@–¼ŒÃ‰®Žs
‚‘º@‰ÀO
“«DME‚ɑ΂·‚éRVEGF–ò‚Ì“K«‚ðl‚¦‚悤
‘æ144‰ñŽRŒ`Šá‰ÈŒ¤‹†‰ï
—ߘa6”N8ŒŽ4“ú@@ŽRŒ`Œ§ŽRŒ`Žs
“«DME‚ɑ΂·‚éRVEGF–ò‚Ì“K«‚ðl‚¦‚悤
‘æ144‰ñŽRŒ`Šá‰ÈŒ¤‹†‰ï
—ߘa6”N8ŒŽ4“ú@@ŽRŒ`Œ§ŽRŒ`Žs
‚‘º@‰ÀO
DME‚Ö‚Ì‘ŠúŽ¡—Éî“ü‚É‚¨‚¯‚éƒxƒIƒrƒ…‚Ö‚ÌŠú‘Ò
Novartis DME Web Seminar
—ߘa6”N8ŒŽ21“ú@Web”zM
DME‚Ö‚Ì‘ŠúŽ¡—Éî“ü‚É‚¨‚¯‚éƒxƒIƒrƒ…‚Ö‚ÌŠú‘Ò
Novartis DME Web Seminar
—ߘa6”N8ŒŽ21“ú@Web”zM
—L‘º@®Œå
‘åŠw•a‰@‚É‚¨‚¯‚é—ΓàáfŽ@
AP-7700 WebƒJƒ“ƒtƒ@ƒŒƒ“ƒXL‚ª‚鎩“®Ž‹–ìŒv‚Ì‘I‘ðŽˆ
—ߘa6”N8ŒŽ23“ú@@Web”zM
‘åŠw•a‰@‚É‚¨‚¯‚é—ΓàáfŽ@
AP-7700 WebƒJƒ“ƒtƒ@ƒŒƒ“ƒXL‚ª‚鎩“®Ž‹–ìŒv‚Ì‘I‘ðŽˆ
—ߘa6”N8ŒŽ23“ú@@Web”zM
ˆî’J@‘å
—Γàá“_Šá–ò2024`Ž¡—ˉ»‚ɂ͔z‡Ü‚©H`
State-of-the-art Šá‰Èf—ÃZƒ~ƒi[
—ߘa6”N9ŒŽ3“ú@@WEB”zM
—Γàá“_Šá–ò2024`Ž¡—ˉ»‚ɂ͔z‡Ü‚©H`
State-of-the-art Šá‰Èf—ÃZƒ~ƒi[
—ߘa6”N9ŒŽ3“ú@@WEB”zM
‚‘º@‰ÀO
“«DME‚ɑ΂µ‚ăoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚·Ž¡—Ãí—ª
VŠƒŒ§ƒoƒr[ƒXƒ‚””„2Žü”N‹L”Ou‰‰‰ï
—ߘa6”N9ŒŽ7“ú@VŠƒŽs
“«DME‚ɑ΂µ‚ăoƒr[ƒXƒ‚‚Ì“Á«‚ð¶‚©‚·Ž¡—Ãí—ª
VŠƒŒ§ƒoƒr[ƒXƒ‚””„2Žü”N‹L”Ou‰‰‰ï
—ߘa6”N9ŒŽ7“ú@VŠƒŽs
‚‘º@‰ÀO
“«DME‚ɑ΂µ‚ătƒ@ƒŠƒVƒ}ƒu‚Ì“Á«‚ð¶‚©‚¹‚é‚©H
‘æ65‰ñ‚Æ‚â‚ÜŠá‰ÈŠwpu‰‰‰ï
—ߘa6”N10ŒŽ5“ú@•xŽRŽs
“«DME‚ɑ΂µ‚ătƒ@ƒŠƒVƒ}ƒu‚Ì“Á«‚ð¶‚©‚¹‚é‚©H
‘æ65‰ñ‚Æ‚â‚ÜŠá‰ÈŠwpu‰‰‰ï
—ߘa6”N10ŒŽ5“ú@•xŽRŽs
ˆî’J@‘å
ƒvƒŠƒU[ƒtƒ‚Ö‚ÌŠú‘Ò
ƒvƒŠƒU[ƒtƒ®ƒ}ƒCƒNƒƒVƒƒƒ“ƒg””„1Žü”N‹L”OWebu‰‰‰ï
—ߘa6”N10ŒŽ9“ú@Web”zM
ƒvƒŠƒU[ƒtƒ‚Ö‚ÌŠú‘Ò
ƒvƒŠƒU[ƒtƒ®ƒ}ƒCƒNƒƒVƒƒƒ“ƒg””„1Žü”N‹L”OWebu‰‰‰ï
—ߘa6”N10ŒŽ9“ú@Web”zM
‚‘º@‰ÀO
DME‚ɑ΂·‚éRVEGFŽ¡—Â̕W€‰»‚Æ’nˆæ˜AŒg
8†üŠá‰È’nˆæ˜AŒg‚̉ï
—ߘa6”N10ŒŽ11“ú@Î쌧
DME‚ɑ΂·‚éRVEGFŽ¡—Â̕W€‰»‚Æ’nˆæ˜AŒg
8†üŠá‰È’nˆæ˜AŒg‚̉ï
—ߘa6”N10ŒŽ11“ú@Î쌧
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2024
‘æ198‰ñ‰ªŽRŒ§Šá‰Èˆã‰ï¶ŠU‹³ˆçuÀ
—ߘa6”N11ŒŽ23“ú@@‰ªŽRŒ§‰ªŽRŽs
[‚ä‚Á‚‚è‰ðà]—Γàá“_Šá–ò2024
‘æ198‰ñ‰ªŽRŒ§Šá‰Èˆã‰ï¶ŠU‹³ˆçuÀ
—ߘa6”N11ŒŽ23“ú@@‰ªŽRŒ§‰ªŽRŽs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá”z‡“_Šá–ò 2025:ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒRI
Glaucoma Update in Aomori
—ߘa7”N1ŒŽ18“ú@ÂXŒ§O‘OŽs
[‚ä‚Á‚‚è‰ðà]—Γàá”z‡“_Šá–ò 2025:ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒRI
Glaucoma Update in Aomori
—ߘa7”N1ŒŽ18“ú@ÂXŒ§O‘OŽs
ˆî’J@‘å
m‚ä‚Á‚‚è‰ðàn—ΓàáŽèpŽ¡—Ã2025
‘æ15‰ñ–k‹ãBR‰Á—îŠá޾гŒ¤‹†‰ï
—ߘa7”N1ŒŽ23“ú@@•Ÿ‰ªŒ§
m‚ä‚Á‚‚è‰ðàn—ΓàáŽèpŽ¡—Ã2025
‘æ15‰ñ–k‹ãBR‰Á—îŠá޾гŒ¤‹†‰ï
—ߘa7”N1ŒŽ23“ú@@•Ÿ‰ªŒ§
ˆî’J@‘å
—ΓàáŽèpŽ¡—ÂÌi•à
Œcœä‹`m‘åŠwˆãŠw•”Šá‰ÈŠw‹³Žº –Ø—jƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa7”N2ŒŽ6“ú@ “Œ‹ž“s
—ΓàáŽèpŽ¡—ÂÌi•à
Œcœä‹`m‘åŠwˆãŠw•”Šá‰ÈŠw‹³Žº –Ø—jƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa7”N2ŒŽ6“ú@ “Œ‹ž“s
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá”z‡“_Šá–ò 2025:ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒRI
ƒOƒ‰ƒAƒ‹ƒtƒ@2Žü”N‹L”Ou‰‰‰ï ROCK Symposium 2025 in ’†Žl‘
—ߘa7”N2ŒŽ22“ú@‰ªŽRŒ§‰ªŽRŽs
[‚ä‚Á‚‚è‰ðà]—Γàá”z‡“_Šá–ò 2025:ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒRI
ƒOƒ‰ƒAƒ‹ƒtƒ@2Žü”N‹L”Ou‰‰‰ï ROCK Symposium 2025 in ’†Žl‘
—ߘa7”N2ŒŽ22“ú@‰ªŽRŒ§‰ªŽRŽs
îà‘º@‰ÀO
“œ”A•a‚É‚æ‚鎸–¾‚ð–h‚®‚½‚߂ɉ½‚ª‚Å‚«‚é‚©H
‘æ54‰ñŠá‰Èˆã—ÃtƒH[ƒ‰ƒ€
—ߘa7”N3ŒŽ9“ú@“¿“‡Žs
“œ”A•a‚É‚æ‚鎸–¾‚ð–h‚®‚½‚߂ɉ½‚ª‚Å‚«‚é‚©H
‘æ54‰ñŠá‰Èˆã—ÃtƒH[ƒ‰ƒ€
—ߘa7”N3ŒŽ9“ú@“¿“‡Žs
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—Γàá”z‡“_Šá–ò 2025 ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒRI
Kowa WEBƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa7”N3ŒŽ13“ú@Web”zM
[‚ä‚Á‚‚è‰ðà]—Γàá”z‡“_Šá–ò 2025 ƒOƒ‰ƒAƒ‹ƒtƒ@‚ÌŽg‚¢‚Ç‚±‚ë‚̓RƒRI
Kowa WEBƒJƒ“ƒtƒ@ƒŒƒ“ƒX
—ߘa7”N3ŒŽ13“ú@Web”zM
ˆî’J@‘å
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
‘æ25‰ñ–kŠC“¹Šá‰ÈƒtƒH[ƒ‰ƒ€
—ߘa7”N3ŒŽ15“ú@–kŠC“¹ŽD–yŽs
[‚ä‚Á‚‚è‰ðà]—ΓàáŽèpŽ¡—Ã2025
‘æ25‰ñ–kŠC“¹Šá‰ÈƒtƒH[ƒ‰ƒ€
—ߘa7”N3ŒŽ15“ú@–kŠC“¹ŽD–yŽs
Žs‹´@—SŽu
“œ”A•a«‰©”Á•‚Žî‚ɑ΂·‚éƒuƒƒ‹ƒVƒYƒ}ƒuŽg—p‘OŒã‚Ì‘O–[“àƒtƒŒƒA‚̕ω»
‘æ8‰ñ–k—¤4‘åŠwŠá‰È‡“¯Œ¤‹†‰ï
—ߘa6”N5ŒŽ17“ú@@•ŸˆäƒtƒFƒjƒbƒNƒXƒzƒeƒ‹
“œ”A•a«‰©”Á•‚Žî‚ɑ΂·‚éƒuƒƒ‹ƒVƒYƒ}ƒuŽg—p‘OŒã‚Ì‘O–[“àƒtƒŒƒA‚̕ω»
‘æ8‰ñ–k—¤4‘åŠwŠá‰È‡“¯Œ¤‹†‰ï
—ߘa6”N5ŒŽ17“ú@@•ŸˆäƒtƒFƒjƒbƒNƒXƒzƒeƒ‹
áÁ“c˜Ð‹GA™Œ´—F‰ÀAîà‘º‰ÀOAŽR“c—Y‹MAJ-CREST groupAˆî’J‘å
“œ”A•a‚ÅŽ‹Šogá‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S‘ŽÀ‘Ô’²¸
‘æ89‰ñ•xŽRŠá‰ÈW’k‰ï
—ߘa6”N6ŒŽ16“ú@@•xŽRŽs
“œ”A•a‚ÅŽ‹Šogá‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S‘ŽÀ‘Ô’²¸
‘æ89‰ñ•xŽRŠá‰ÈW’k‰ï
—ߘa6”N6ŒŽ16“ú@@•xŽRŽs
´…ç—ÇA™Œ´—F‰ÀAîà‘º‰ÀOAŽR“c—Y‹MAJ-CREST groupAˆî’J‘å
“œ”A•a‚ÅŽ‹Šogá‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S‘ŽÀ‘Ô’²¸
‘æ79‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa6”N9ŒŽ7“ú@•Ÿˆä¤H‰ï‹cŠ
“œ”A•a‚ÅŽ‹Šogá‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S‘ŽÀ‘Ô’²¸
‘æ79‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa6”N9ŒŽ7“ú@•Ÿˆä¤H‰ï‹cŠ
Šâí•@Œ’‘¾˜Y
ŒŒŠÇV¶—Γàá‚ɑ΂·‚éƒoƒ‹ƒxƒ‹ƒg‚Ì—LŒø«
‘æ14‰ñ—Γàáƒ`ƒ…[ƒuŽèp‚̉ï
—ߘa6”N11ŒŽ16“ú@ƒzƒeƒ‹ƒI[ƒNƒ‰‹ž“s
ŒŒŠÇV¶—Γàá‚ɑ΂·‚éƒoƒ‹ƒxƒ‹ƒg‚Ì—LŒø«
‘æ14‰ñ—Γàáƒ`ƒ…[ƒuŽèp‚̉ï
—ߘa6”N11ŒŽ16“ú@ƒzƒeƒ‹ƒI[ƒNƒ‰‹ž“s
—F“cÊ…A™Œ´—F‰ÀAîà‘º‰ÀOAŽR“c—Y‹MAJ-CREST groupAˆî’J‘å
“œ”A•a‚ÅŽ‹Šogá‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S‘ŽÀ‘Ô’²¸
‘æ44‰ñ‹à‘òˆã‰È‘åŠwŠá‰ÈŒ¤‹†‰ï
—ߘa6”N11ŒŽ16“ú@@‹à‘òŽs
“œ”A•a‚ÅŽ‹Šogá‚Æ”F’肳‚ê‚½Š³ŽÒ‚Ì‘S‘ŽÀ‘Ô’²¸
‘æ44‰ñ‹à‘òˆã‰È‘åŠwŠá‰ÈŒ¤‹†‰ï
—ߘa6”N11ŒŽ16“ú@@‹à‘òŽs
áÁ“c˜Ð‹GAŠâ핌’‘¾˜YA¬X—Á•½A—L‘º®ŒåA‚‘º‰ÀOAˆî’J‘å
Šá“àƒŒƒ“ƒYˆŸ’E‰P—Γàá‚ɑ΂·‚éŠá“àƒŒƒ“ƒYČŒèp‚̊ሳ‰º~Œø‰Ê
‘æ90‰ñ•xŽRŠá‰ÈW’k‰ï
—ߘa6”N11ŒŽ23“ú@•xŽRŽs
Šá“àƒŒƒ“ƒYˆŸ’E‰P—Γàá‚ɑ΂·‚éŠá“àƒŒƒ“ƒYČŒèp‚̊ሳ‰º~Œø‰Ê
‘æ90‰ñ•xŽRŠá‰ÈW’k‰ï
—ߘa6”N11ŒŽ23“ú@•xŽRŽs
áÁ“c˜Ð‹GAŠâ핌’‘¾˜YA¬X—Á•½A—L‘º®ŒåA‚‘º‰ÀOAˆî’J‘å
Šá“àƒŒƒ“ƒYˆŸ’E‰P—Γàá‚ɑ΂·‚éŠá“àƒŒƒ“ƒYČŒèp‚̊ሳ‰º~Œø‰Ê
‘æ353‰ñ‹à‘òŠá‰ÈW’k‰ï
—ߘa6”N12ŒŽ15“ú@‹à‘òŽs
Šá“àƒŒƒ“ƒYˆŸ’E‰P—Γàá‚ɑ΂·‚éŠá“àƒŒƒ“ƒYČŒèp‚̊ሳ‰º~Œø‰Ê
‘æ353‰ñ‹à‘òŠá‰ÈW’k‰ï
—ߘa6”N12ŒŽ15“ú@‹à‘òŽs
áÁ“c˜Ð‹G
’·ŠúŽûÚ•i‚ɑ΂·‚é‘I’è—×{‚Ç‚¤‚µ‚Ä‚éH
‘æ80‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa7”N1ŒŽ11“ú@•Ÿˆä¤H‰ï‹cŠ
’·ŠúŽûÚ•i‚ɑ΂·‚é‘I’è—×{‚Ç‚¤‚µ‚Ä‚éH
‘æ80‰ñ•ŸˆäŒ§Šá‰ÈW’k‰ï
—ߘa7”N1ŒŽ11“ú@•Ÿˆä¤H‰ï‹cŠ
Œã‘ò@½
’¿‚µ‚¢Šá‹…”j—ô‚̈ê—á
‘æ5‰ñ–Ô–ŒHOPE‚̉ï
—ߘa7”N3ŒŽ7“ú@Web”zM
’¿‚µ‚¢Šá‹…”j—ô‚̈ê—á
‘æ5‰ñ–Ô–ŒHOPE‚̉ï
—ߘa7”N3ŒŽ7“ú@Web”zM
‰ß‹Ž‚Ì‹ÆÑ
Šw‰ï”•\@2024
Šw‰ï”•\@2023
Šw‰ï”•\@2022
Šw‰ï”•\@2021
Šw‰ï”•\@2020
Šw‰ï”•\@2019
Šw‰ï”•\@2018
Šw‰ï”•\@2017
Šw‰ï”•\@2016
Šw‰ï”•\@2015
Šw‰ï”•\@2014
Šw‰ï”•\@2013
Šw‰ï”•\@2012





![“ü‹Ç‚ðŠó–]‚·‚éŠF—l‚Ö](../../images/global_05.png)

